CandlesenseCandlesense
AIMClinical Trials•globenewswire•

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

Sentiment:Positive (70)

Summary

(AIM) Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025); Presentation now available here

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on September 4, 2025 by globenewswire

← Back to AIM News
    AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland | AIM Stock News | Candlesense